Literature DB >> 27111654

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

Qian Chen1, Zhuang Liu1.   

Abstract

Theranostic nanoplatforms with integrated diagnostic and therapeutic functions, aiming at imaging-guided therapy to improve treatment planning, as well as combination therapy to enhance treatment efficacy, have received tremendous attention in recent years. Among numerous types of functional nanomaterials explored in this field, protein-based nanocarriers with inherent biocompatibility have also been selected as building blocks to construct multifunctional theranostic platforms. In particular, albumin, which has been extensively used as drug-delivery carriers for decades, has shown great new promise in the construction of novel imaging and therapeutic nanoagents, as demonstrated by a number of recent studies. IHere, the motivations of using albumins to build up nanoscale theranostics are discussed, and the latest progress/future perspectives in this direction are summarized.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  albumin; cancer therapy; imaging; nanoplatforms; theranostics

Mesh:

Substances:

Year:  2016        PMID: 27111654     DOI: 10.1002/adma.201600038

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  33 in total

1.  A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.

Authors:  Yong Bo Peng; Zi Long Zhao; Teng Liu; Guo Jian Xie; Cheng Jin; Tang Gang Deng; Yang Sun; Xiong Li; Xiao Xiao Hu; Xiao Bing Zhang; Mao Ye; Wei Hong Tan
Journal:  ChemMedChem       Date:  2017-01-18       Impact factor: 3.466

2.  Regulating the alky chain length of fatty acid-didanosine prodrugs and evaluating its role in albumin binding.

Authors:  Hongxiang Chen; Gang Wang; Lanzhen Sun; Huicong Zhang; Mengchi Sun; Jin Sun; Lei Shang; Cong Luo
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 3.  Deciphering albumin-directed drug delivery by imaging.

Authors:  Huiyu Hu; Jeremy Quintana; Ralph Weissleder; Sareh Parangi; Miles Miller
Journal:  Adv Drug Deliv Rev       Date:  2022-03-29       Impact factor: 17.873

4.  Protein Based Biomaterials for Therapeutic and Diagnostic Applications.

Authors:  Stanley Chu; Andrew L Wang; Aparajita Bhattacharya; Jin Kim Montclare
Journal:  Prog Biomed Eng (Bristol)       Date:  2021-10-26

5.  Albumin-Gold Nanorod Nanoplatform for Cell-Mediated Tumoritropic Delivery with Homogenous ChemoDrug Distribution and Enhanced Retention Ability.

Authors:  Hsien-Ting Chiu; Cheng-Kuan Su; Yuh-Chang Sun; Chi-Shiun Chiang; Yu-Fen Huang
Journal:  Theranostics       Date:  2017-07-22       Impact factor: 11.556

6.  Förster Resonance Energy Transfer-Based Dual-Modal Theranostic Nanoprobe for In Situ Visualization of Cancer Photothermal Therapy.

Authors:  Dehong Hu; Zonghai Sheng; Mingting Zhu; Xiaobing Wang; Fei Yan; Chengbo Liu; Liang Song; Ming Qian; Xin Liu; Hairong Zheng
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

7.  Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer.

Authors:  Longlong Tian; Qian Chen; Xuan Yi; Guanglin Wang; Jie Chen; Ping Ning; Kai Yang; Zhuang Liu
Journal:  Theranostics       Date:  2017-01-12       Impact factor: 11.556

8.  Hypoxia-responsive nanoreactors based on self-enhanced photodynamic sensitization and triggered ferroptosis for cancer synergistic therapy.

Authors:  Xiaoyan Wang; Ming Wu; Xiaolong Zhang; Feida Li; Yongyi Zeng; Xinyi Lin; Xiaolong Liu; Jingfeng Liu
Journal:  J Nanobiotechnology       Date:  2021-07-08       Impact factor: 10.435

Review 9.  Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery.

Authors:  Fei-Fei An; Xiao-Hong Zhang
Journal:  Theranostics       Date:  2017-08-23       Impact factor: 11.556

10.  Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1).

Authors:  Minzhi Zhao; Haiyun Li; Yan Ma; He Gong; Shu Yang; Qiaojun Fang; Zhiyuan Hu
Journal:  Int J Nanomedicine       Date:  2017-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.